As the result of the rarity of appendix cancer (appendix cancer accounts for less than 1 percent of tumors that originate in the gastrointestinal tract), there is a lack of scientific data to guide treatment decisions. As a result, current treatment guidelines are the same as for colon cancer.
Researchers from Yale Cancer Center have found that PARP Inhibitors might offer an effective treatment paradigm for two rare inherited cancers, Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) and Succinate Dehydrogenase-related Hereditary Paraganglioma and Pheochromocytoma (SDH PGL/PCC).
The European Union has recently placed some restrictions on the use of the MRI contrast agent Gadolinium. There has been concern expressed by recent findings that Gadolinium doesn’t wholly disappear or wash out of a person’s body, but instead stays in a person’s brain.
The Scottish Medicines Consortium (SMC) has advised against two cancer medications for rare cancers because it determined that their cost outweighed their benefits.
The FDA has just expanded the use of Afatinib as a first line treatment to include a rare subset of people with metastatic non-small cell lung cancer (NSCLC)
In a recently published study, it was shown that more than two-thirds of people with a rare type of melanoma, Desmoplastic Melanoma, responded to treatment with anti-PD-1 immunotherapies.
During a multi-omics analysis of the rare nasal cancer, olfactory neuroblastoma researchers tracked down potential protein markers for treatment response or resistance.
The American Society of Clinical Oncology (ACSO), warns that people drinking alcoholic drinks face a significantly increased risk of developing cancer(s).
Foundation One has announced that The Food and Drug Administration (FDA) has approved a “breakthrough device” that has the potential to match cancer patients with more accurate individualized treatment regiments with just one test. This test will push the boundaries of personalized medicine as it might allow us to choose better treatments that are most likely to be effective for specific types of cancer — and to make those decisions sooner.
Research has shown that chemo brain may come from the cancer tumor itself as well as from treatment.
Shingles can be a very debilitating disease. There is now a newly approved vaccine which you should consider getting.
An article in Healio (10/23) reported the results of a study of 120 cancer patients “nearly three-quarters of patients with advanced cancer preferred doctors who communicated with them face-to-face while holding a notepad rather than repeatedly using a computer.”
Hello, why the surprise here?
In a presentation scheduled to be delivered at the Palliative and Supportive Care in Oncology Symposium, Andrew S. Epstein, MD, ASCO expert and medical oncologist at Memorial Sloan Kettering Cancer Center, said of the research implications, “In an age of ubiquitous technology, this study is an important reminder of the need to address the potential for technology to interfere with the patient-clinician interface, which is a critical component of the relationship between these two parties.”
Look, we already know this fact. The real question for us isn’t the research finding, but what we need to do if we find that our doctor doesn’t speak with us but instead engages with the computer screen.
Usually, physicians engage with the computer during our meetings with them so that their notes are up to date without needing to take a few seconds afterward and update their notes. Doctors who engage in this practice are being selfish.
Forget our personal preferences that we want to feel that our doctors engage with us; there is good evidence that a doctor can gain as much valuable clinical information about us by carefully observing us as well as listening to what we say to them.
The standard of care should dictate that our clinical caregivers engage us, not their computer.
Joel T. Nowak, MA, MSW wrote this Post. Joel is the CEO/Executive Director of Cancer ABCs. He is a Cancer Thriver diagnosed with five primary cancers - Thyroid, Metastatic Prostate, Renal, Melanoma, and Appendiceal Cancer
a rare cancer.
More than a majority of cancer patients do not understand that if they enter into a clinical trial they have no guarantee that they will receive the investigational treatment that they believe their doctor wants them to receive! More transparent clinical trial consenting procedures need to be immediately instituted.
Medicare Open Enrollment starts on October 15th. If you are on Medicare this short period can be very important for your health.
Even a doctor can face a poorly made cancer diagnosis as well as patronizing and resistant physicians. Dr. Sajjad Iqbal faced both and won.
We are lacking adequate numbers of and reliable prognostic tools to guide our treatment decisions. There needs to be a commitment to increasing research across all cancers to develop these needed tools.
Our drugs have more than one name for the same drug. How does this confusion develop?
Good news out of the European Medicines Agency for Medicinal Products for Human Use (CHMP), four recommednded approvals for cancer treatments.
We are on the verge of a new, game-changing type of cancer treatment - Gene Therapy